In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans.

Aureobasidium pullulans is an unusual agent of phaeohyphomycosis. The in vitro activities of antifungals against 104 isolates of Aureobasidium pullulans var. pullulans and A. pullulans var. melanigenum revealed low MIC90s of amphotericin B, posaconazole, and itraconazole. However, they were resistant to fluconazole (≥64 µg/ml) and had high MICs of voriconazole, isavuconazole, caspofungin, and micafungin.

In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.

Cyphellophora guyanensis (n = 15), other Cyphellophora species (n = 11), Phialophora europaea (n = 43), and other Phialophora species (n = 12) were tested in vitro against nine antifungal drugs. The MIC(90)s across all of the strains (n = 81) were, in increasing order, as follows: posaconazole, 0.063 µg/ml; itraconazole, 0.5 µg/ml; voriconazole, 1 µg/ml; micafungin, 1 µg/ml; terbinafine, 2 µg/ml; isavuconazole, 4 µg/ml; caspofungin, 4 µg/ml; fluconazole, 8 µg/ml; amphotericin B, 16 µg/ml.

Genome Sequence of Type Strain Fonsecaea multimorphosa CBS 980.96T, a Causal Agent of Feline Cerebral Phaeohyphomycosis.

A draft genome sequence of type strain Fonsecaea multimorphosa CBS 980.96T was obtained. This species was first isolated from a cat with cerebral phaeohyphomycosis in Queensland, Australia.

Draft Genome Sequence of Fonsecaea nubica Strain CBS 269.64, Causative Agent of Human Chromoblastomycosis.

On the basis of multilocus phylogenetic data, Fonsecaea nubica was described in 2010 as a molecular sibling of F. monophora, an established agent of the human skin disease chomoblastomycosis in tropical zones. Genome analysis of these pathogens is mandatory to identify genes involved in the interaction with host and virulence.